Welcome to our dedicated page for Alx Oncology Holdings news (Ticker: ALXO), a resource for investors and traders seeking the latest updates and insights on Alx Oncology Holdings stock.
ALX Oncology Holdings Inc. (NASDAQ: ALXO) is a clinical-stage immuno-oncology company advancing novel therapies targeting the CD47 checkpoint pathway. This page provides investors and industry professionals with essential updates on evorpacept development, strategic partnerships, and clinical trial progress.
Access consolidated news about ALXO’s innovative approach to enhancing cancer treatment through engineered CD47 blockade. Stay informed about regulatory milestones, research collaborations, and financial disclosures that shape the company’s trajectory in oncology drug development.
Key updates include clinical trial results for evorpacept combination therapies, FDA communications, and scientific presentations. All content is curated to support informed analysis of ALXO’s position in the competitive immuno-oncology landscape.
Bookmark this page for streamlined access to verified ALX Oncology announcements. Check regularly for developments in hematologic and solid tumor research programs leveraging the company’s proprietary protein engineering platform.
ALX Oncology Holdings Inc. (ALXO) announced a loan agreement for up to $100 million of non-dilutive financing with Oxford Finance and Silicon Valley Bank. This funding will support the development of evorpacept, a CD47 blocking therapeutic. ALX has accessed $10 million of an initial $50 million tranche, with the remaining funds available at its discretion through 2023. The financing extends their cash runway to mid-2025, allowing for further clinical trials and milestones.
ALX Oncology (Nasdaq: ALXO) announced the acceptance of two Trials in Progress abstracts for ASPEN-03 and ASPEN-04, Phase 2 studies on advanced head and neck cancer, at the SITC 37th Annual Meeting in Boston from November 8-12, 2022. The abstracts detail studies on evorpacept (ALX148) combined with pembrolizumab, with session times on November 10-11, 2022. ALX Oncology focuses on developing therapies that block the CD47 checkpoint pathway, with evorpacept showing promising results for various cancers.
ALX Oncology Holdings Inc. (Nasdaq: ALXO), a clinical-stage immuno-oncology company, announced its participation in the Cantor Oncology, Hematology & HemeOnc Conference on September 28, 2022, in New York. CEO Jaume Pons, Ph.D., will be part of a moderated panel titled “Building Combinations: What are the Novel Ideas?” at 10:40 AM ET. Additionally, Dr. Pons and CFO Peter Garcia will conduct one-on-one investor meetings during the event. ALX Oncology is advancing its lead product candidate, evorpacept, aimed at treating various cancers by blocking the CD47 checkpoint pathway.
ALX Oncology Holdings Inc. (Nasdaq: ALXO), a clinical-stage immuno-oncology company, announced participation in two investor conferences. The first is Citi's 17th Annual BioPharma Conference on September 7 in Boston, MA. The second event is the H.C. Wainwright 24th Annual Global Investment Conference on September 12, featuring a fireside chat with analyst Swayampakula Ramakanth at 7:00 AM Eastern Time, available virtually. ALX is focused on developing therapies that target the CD47 checkpoint pathway, with promising results for its lead candidate, evorpacept.
ALX Oncology Holdings Inc. (Nasdaq: ALXO) announced the selection of its CD47 blocker, evorpacept, for an investigational arm in the I-SPY-P1 TRIAL, targeting HER2-positive and HER2-low breast cancer. This Phase 1 study, sponsored by Quantum Leap Healthcare Collaborative, will explore evorpacept in combination with ENHERTU (fam-trastuzumab deruxtecan-nxki) to assess safety and efficacy. The trial aims to address the need for effective treatments in patients resistant to other therapies, with ALX providing funding and drug supply.
ALX Oncology Holdings (Nasdaq: ALXO) has announced that its CD47 blocker, evorpacept, has been selected for a new investigational treatment arm in the I-SPY-P1 TRIAL. This partnership with Quantum Leap Healthcare Collaborative will evaluate the safety and efficacy of evorpacept combined with ENHERTU for patients with HER2-positive and HER2-low breast cancer. The study aims to provide novel treatment options for advanced breast cancer patients who have developed resistance to existing therapies. ALX will supply evorpacept and fund the study, while Quantum Leap manages the trial.
ALX Oncology (Nasdaq: ALXO) announced the initiation of a Phase 2 investigator-sponsored study for evorpacept, a CD47 blocker. The trial aims to assess the drug's efficacy in combination with ERBITUX® and KEYTRUDA® in patients with refractory microsatellite stable metastatic colorectal cancer (mCRC) who have failed at least two systemic therapies. With notable collaboration from Merck and Eli Lilly, the study is expected to address a significant medical need, given the low 5-year survival rate of 15.1% for metastatic CRC patients. Findings from prior studies indicated promising activity and tolerability for evorpacept.
ALX Oncology Holdings Inc. (Nasdaq: ALXO) reported its Q2 2022 financial results, showcasing significant advancements in its lead therapeutic, evorpacept. The FDA granted Fast Track designation for evorpacept in treating advanced head and neck squamous cell carcinoma, alongside Orphan Drug Designation for acute myeloid leukemia. R&D expenses surged to $26.7 million from $11.2 million YOY. The company holds $324.2 million in cash, projected to fund operations until Q4 2024, despite a net loss of $32.9 million for the quarter.
ALX Oncology has announced that the FDA has granted Fast Track designation for evorpacept, a CD47 blocker combined with KEYTRUDA, for first-line treatment of advanced head and neck squamous cell carcinoma (HNSCC). Preliminary results from the phase 1 ASPEN-01 trial showed a 40% objective response rate in patients previously treated with checkpoint inhibitors. This designation aims to expedite development for serious conditions. HNSCC is a critical health issue, with an expected rise in incidence.
Tallac Therapeutics has initiated a Phase 1/2 clinical trial for TAC-001, its lead candidate from the innovative Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform, marking a significant milestone. This trial, named INCLINE-101, aims to assess the safety and preliminary anti-tumor activity of TAC-001 in patients with advanced solid tumors. The company plans to file an investigational new drug application (IND) for its second candidate, ALTA-002, in early next year, further advancing its promising pipeline in cancer immunotherapy.
